Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea
· Delayed Price · Currency is KRW 6,390.00
-60.00 (-0.93%)
At close: Mar 28, 2025, 3:30 PM KST
Sinil Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 89,440 | 89,135 | 80,007 | 61,754 | 61,438 | Upgrade
|
| Other Revenue | -0 | - | -0 | - | - | Upgrade
|
| Revenue | 89,440 | 89,135 | 80,007 | 61,754 | 61,438 | Upgrade
|
| Revenue Growth (YoY) | 0.34% | 11.41% | 29.56% | 0.52% | 1.30% | Upgrade
|
| Cost of Revenue | 48,774 | 51,565 | 44,362 | 37,313 | 37,234 | Upgrade
|
| Gross Profit | 40,666 | 37,570 | 35,645 | 24,441 | 24,204 | Upgrade
|
| Selling, General & Admin | 21,238 | 19,491 | 17,623 | 15,574 | 15,522 | Upgrade
|
| Research & Development | 2,802 | 2,979 | 3,264 | 194.52 | 784.55 | Upgrade
|
| Other Operating Expenses | 347.33 | 355.82 | 378.68 | 374.75 | 395.92 | Upgrade
|
| Operating Expenses | 25,445 | 23,579 | 21,989 | 16,459 | 17,583 | Upgrade
|
| Operating Income | 15,222 | 13,991 | 13,656 | 7,982 | 6,621 | Upgrade
|
| Interest Expense | -26.97 | -26.13 | -6.05 | -9.72 | -13.24 | Upgrade
|
| Interest & Investment Income | 1,074 | 849.37 | 352.84 | 184.48 | 224.04 | Upgrade
|
| Currency Exchange Gain (Loss) | 43.68 | -59.59 | 90.91 | 26.14 | 4.22 | Upgrade
|
| Other Non Operating Income (Expenses) | 217.24 | 1,379 | 899.91 | 14.64 | 1,226 | Upgrade
|
| EBT Excluding Unusual Items | 16,530 | 16,134 | 14,994 | 8,197 | 8,062 | Upgrade
|
| Gain (Loss) on Sale of Investments | -26.81 | -532.61 | -478.44 | 115.48 | -11.37 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.72 | -641.55 | 221.3 | 14 | 13.42 | Upgrade
|
| Asset Writedown | 31 | -7 | -92.08 | 14.5 | 97.5 | Upgrade
|
| Pretax Income | 16,538 | 14,953 | 14,645 | 8,341 | 8,162 | Upgrade
|
| Income Tax Expense | 2,237 | 1,312 | 2,488 | 1,663 | 617.51 | Upgrade
|
| Net Income | 14,301 | 13,641 | 12,157 | 6,679 | 7,544 | Upgrade
|
| Net Income to Common | 14,301 | 13,641 | 12,157 | 6,679 | 7,544 | Upgrade
|
| Net Income Growth | 4.83% | 12.21% | 82.02% | -11.47% | 3.96% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | 0.00% | 3.93% | -0.07% | -0.97% | -0.08% | Upgrade
|
| EPS (Basic) | 1237.00 | 1180.00 | 1092.89 | 600.00 | 671.15 | Upgrade
|
| EPS (Diluted) | 1237.00 | 1180.00 | 1092.89 | 600.00 | 671.15 | Upgrade
|
| EPS Growth | 4.83% | 7.97% | 82.15% | -10.60% | 4.04% | Upgrade
|
| Free Cash Flow | 12,327 | 1,551 | 3,336 | 7,820 | 2,261 | Upgrade
|
| Free Cash Flow Per Share | 1066.28 | 134.15 | 299.94 | 702.52 | 201.11 | Upgrade
|
| Gross Margin | 45.47% | 42.15% | 44.55% | 39.58% | 39.40% | Upgrade
|
| Operating Margin | 17.02% | 15.70% | 17.07% | 12.93% | 10.78% | Upgrade
|
| Profit Margin | 15.99% | 15.30% | 15.20% | 10.81% | 12.28% | Upgrade
|
| Free Cash Flow Margin | 13.78% | 1.74% | 4.17% | 12.66% | 3.68% | Upgrade
|
| EBITDA | 20,828 | 19,353 | 18,088 | 12,518 | 11,053 | Upgrade
|
| EBITDA Margin | 23.29% | 21.71% | 22.61% | 20.27% | 17.99% | Upgrade
|
| D&A For EBITDA | 5,607 | 5,361 | 4,432 | 4,536 | 4,432 | Upgrade
|
| EBIT | 15,222 | 13,991 | 13,656 | 7,982 | 6,621 | Upgrade
|
| EBIT Margin | 17.02% | 15.70% | 17.07% | 12.93% | 10.78% | Upgrade
|
| Effective Tax Rate | 13.53% | 8.77% | 16.99% | 19.93% | 7.57% | Upgrade
|
| Advertising Expenses | 980.01 | 1,059 | 140.42 | 157.25 | 206.15 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.